1. Home
  2. TROO vs CTNM Comparison

TROO vs CTNM Comparison

Compare TROO & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TROOPS Inc.

TROO

TROOPS Inc.

HOLD

Current Price

$2.28

Market Cap

480.1M

Sector

Technology

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$13.42

Market Cap

507.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TROO
CTNM
Founded
2005
2009
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
480.1M
507.0M
IPO Year
2008
2024

Fundamental Metrics

Financial Performance
Metric
TROO
CTNM
Price
$2.28
$13.42
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$19.00
AVG Volume (30 Days)
153.7K
327.6K
Earning Date
04-29-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.46
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$3.35
52 Week High
$5.28
$16.33

Technical Indicators

Market Signals
Indicator
TROO
CTNM
Relative Strength Index (RSI) 38.37 50.07
Support Level $0.74 $10.17
Resistance Level $2.74 $15.80
Average True Range (ATR) 0.29 1.01
MACD -0.02 0.08
Stochastic Oscillator 46.84 68.33

Price Performance

Historical Comparison
TROO
CTNM

About TROO TROOPS Inc.

TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: